Cargando…
Diagnosis of Transthyretin Amyloid Cardiomyopathy
Transthyretin amyloid cardiomyopathy (ATTR-CM) continues to be an easily overlooked, life-threatening, yet treatable cause of heart failure. Furthermore, its elusive diagnosis leads to late or misdiagnosis. As therapeutic advancements such as tafamidis usher in a promising new era in the management...
Autores principales: | Hafeez, Adam S., Bavry, Anthony A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237598/ https://www.ncbi.nlm.nih.gov/pubmed/32266575 http://dx.doi.org/10.1007/s40119-020-00169-4 |
Ejemplares similares
-
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023) -
Hereditary transthyretin amyloid cardiomyopathy
por: Zheng, Yiliang, et al.
Publicado: (2023) -
Multi-modality imaging in transthyretin amyloid cardiomyopathy
por: Traynor, Bryan Paul, et al.
Publicado: (2019) -
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy
por: Nuvolone, Mario, et al.
Publicado: (2022) -
Speckle Tracking and Transthyretin Amyloid
Cardiomyopathy
por: Rocha, Alexandre Marins, et al.
Publicado: (2017)